Literature DB >> 8923094

Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.

P M Haffmans1, L Timmerman, C A Hoogduin.   

Abstract

In 16 depression clinics in hospitals and outpatient facilities in the Netherlands, a study was performed to evaluate and compare the efficacy and tolerability of citalopram and fluvoxamine and to determine the difference in the incidence of gastrointestinal side-effects. A total of 217 patients with a depressive disorder (DSM-III-R criteria) and a score of at least 16 on the Hamilton rating scale for depression were randomized to treatment. The results of this study indicate that the two drugs are equally effective. The adverse events occurring during treatment show a similar pattern between the two drugs, but citalopram is better tolerated than fluvoxamine. Citalopram induces fewer gastrointestinal adverse events compared with fluvoxamine. However, this did not affect the drop-out rates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923094     DOI: 10.1097/00004850-199609000-00002

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  12 in total

1.  Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system.

Authors:  O Spigset
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

2.  Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features.

Authors:  Patricia A. Marken; J Stuart Munro
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

Review 3.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 4.  Selective serotonin reuptake inhibitors for late-life depression: a comparative review.

Authors:  L K Solai; B H Mulsant; B G Pollock
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Fluvoxamine versus other anti-depressive agents for depression.

Authors:  Ichiro M Omori; Norio Watanabe; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 6.  Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.

Authors:  Barbara Nussbaumer; Laura C Morgan; Ursula Reichenpfader; Amy Greenblatt; Richard A Hansen; Megan Van Noord; Linda Lux; Bradley N Gaynes; Gerald Gartlehner
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

7.  Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Authors:  J G Edwards; I Anderson
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 8.  Citalopram versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Marianna Purgato; Toshi A Furukawa; Carlotta Trespidi; Giuseppe Imperadore; Alessandra Signoretti; Rachel Churchill; Norio Watanabe; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

9.  Citalopram in anorexia nervosa.

Authors:  S Pallanti; L Quercioli; A Ramacciotti
Journal:  Eat Weight Disord       Date:  1997-12       Impact factor: 4.652

Review 10.  Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

Authors:  Gerald Gartlehner; Patricia Thieda; Richard A Hansen; Bradley N Gaynes; Angela Deveaugh-Geiss; Erin E Krebs; Kathleen N Lohr
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.